Yinuo Pharmaceuticals-B (02591.HK): Received approval from the National Medical Products Administration to conduct Phase Ib clinical trials of exenatide for the treatment of adolescent obesity.

Wisdom Financial News APP News, Yinuo Pharmaceuticals-B (02591.HK) announced that on June 17, 2026, the group received approval from the China National Medical Products Administration to conduct phase Ib clinical trials for the use of the group's supaglutide in the treatment of adolescent obesity. The company expects the clinical trial to begin in July 2026 and plans to recruit approximately 36 participants for the trial.